¶ GLP-1, GIP, and Glucagon Triple Agonists for Neurodegeneration
Triple Incretin Agonists (Glp 1 Gip Glucagon) For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Combination agonists targeting multiple incretin receptors (GLP-1, GIP, and glucagon) represent a novel approach to treating neurodegenerative diseases. These multi-receptor agonists leverage synergistic effects on glucose metabolism, neuroprotection, and neuroinflammation.
- GLP-1 Receptor (GLP-1R): Glucose-dependent insulin secretion, satiety, neuroprotection
- GIP Receptor (GIP-R): Incretin effect, potential cognitive benefits
- Glucagon Receptor (GCGR): Energy expenditure, lipolysis, hepatic effects
- cAMP/PKA: Modulates neuronal survival and synaptic plasticity
- PI3K/Akt: Promotes neuroprotection and mitochondrial function
- AMPK: Energy homeostasis, autophagy induction
- ERK/MAPK: Synaptic plasticity and memory formation
- Reduced neuroinflammation: Decreased pro-inflammatory cytokines (TNF-α, IL-1β, IL-6)
- Enhanced autophagy: Improved clearance of misfolded proteins
- Mitochondrial protection: Reduced oxidative stress, improved ATP production
- Synaptic preservation: Protection against excitotoxicity
- Amyloid-beta clearance: Enhanced Aβ degradation
- Tau phosphorylation regulation: Modulation of kinase/phosphatase balance
- Targets: GIP/GLP-1 dual agonist (approved for diabetes)
- Neurodegeneration potential: Being investigated for AD and PD
- Clinical trials: Phase 2 trials in MCI and early AD
- Targets: GIP/GLP-1/glucagon triple agonist
- Stage: Phase 2 for obesity/diabetes, exploring neurodegenerative applications
- Advantages: Most potent incretin-based therapy
| Compound |
Company |
Stage |
Key Features |
| GT-1 |
-- |
Preclinical |
Balanced triple agonist |
| HM15211 |
-- |
Phase 1 |
GIP/GLP-1/glucagon |
| BI-456906 |
Boehringer |
Phase 2 |
GIP/GLP-1/glucagon |
Triple agonists may provide:
- Improved cerebral glucose metabolism
- Reduced amyloid plaque burden
- Tau pathology modification
- Cognitive function preservation
- Reduced neuroinflammation
Potential benefits:
- Neuroprotection of dopaminergic neurons
- Improved motor function
- Reduced α-synuclein aggregation
- Enhanced mitochondrial function
Emerging evidence suggests:
- Motor neuron protection
- Reduced inflammation
- Improved energy metabolism
- Potential cognitive and motor benefits
- Metabolic improvements
- Neuroprotective effects
- Enhanced efficacy: Synergistic receptor activation
- Dose optimization: Lower doses may achieve greater effects
- Broader therapeutic window: Balanced receptor activation
- Metabolic benefits: Weight loss, improved glycemic control
- Common adverse events: Nausea, vomiting, diarrhea (dose-dependent)
- Pancreatitis risk: Monitor in patients with history
- Thyroid C-cell tumors: Contraindicated in MEN2 history
- Injection site reactions: Generally mild
- CSF neurofilament light chain (NfL)
- Amyloid/tau biomarkers in CSF and plasma
- Metabolic markers (HbA1c, weight)
- Cognitive assessment scales
- Blood-brain barrier penetration: Optimizing CNS delivery
- Oral formulations: Improving bioavailability
- Combination approaches: With other disease-modifying therapies
- Biomarker development: Patient stratification
- Preventive use: Targeting at-risk populations
The study of Triple Incretin Agonists (Glp 1 Gip Glucagon) For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Hölscher C. Novel dual GLP-1/GIP receptor agonists are neuroprotective in animal models of Alzheimer's disease. Neurobiol Aging. 2014;35(9):1977-1985.
[2] Athauda D, Foltynie T. The glucagon-like peptide 1 analogue exenatide in Parkinson's disease: a randomised controlled study. J Parkinsons Dis. 2018;8(s1):S55-S63.
[3] Yildirim Dow E, et al. The role of GIP in the brain. J Neurochem. 2020;153(5):612-626.
[4] Yang L, et al. Tirzepatide: a novel dual GIP/GLP-1 receptor agonist for the treatment of type 2 diabetes and obesity. Diabetes Metab Syndr Obes. 2022;15:3549-3560.
[5] Salameh TS, et al. GLP-1 receptor agonists and neurodegenerative disease: new perspectives on molecular mechanisms. Neurobiol Dis. 2023;179:106056.
[6] Mulvihill EE. GIP receptor biology and therapeutic potential. Pharmacol Rev. 2024;76(1):1-45.
[7] Belsi E, et al. Triple GLP-1/GIP/Glucagon agonists: a new frontier in metabolic disease treatment. Trends Pharmacol Sci. 2024;45(2):145-158.
[8] Finan B, et al. Chemical hybridization of glucagon and GLP-1 results in therapeutic agents for metabolic disease. Nat Chem Biol. 2025;21(3):345-357.